Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target

  title={Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target},
  author={Richard L. Eckert},
  journal={Molecular Carcinogenesis},
  pages={837 - 853}
  • R. Eckert
  • Published 2019
  • Biology, Medicine
  • Molecular Carcinogenesis
Transglutaminase 2 (TG2) has emerged as a key cancer cell survival factor that drives epithelial to mesenchymal transition, angiogenesis, metastasis, inflammation, drug resistance, cancer stem cell survival and stemness, and invasion and migration. TG2 can exist in a GTP‐bound signaling‐active conformation or in a transamidase‐active conformation. The GTP bound conformation of TG2 contributes to cell survival and the transamidase conformation can contribute to cell survival or death. We present… Expand
Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
TG2 is identified as a direct SFN anticancer target in epidermal squamous cell carcinoma using a biotin-tagged SFN analog (Biotin-ITC) and kinetic analysis and shows that SFN covalently and irreversibly binds to recombinant TG2 to inhibit transamidase activity and shiftTG2 to an open/extended conformation, leading to a partial inhibition of GTP binding. Expand
The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment
The wide array of processes in which TG2 influences the TME is highlighted, focussing on its potential role in the dynamic tissue remodelling and biomechanical events increasingly linked to invasive and aggressive behaviour. Expand
Tissue transglutaminase in fibrosis — more than an extracellular matrix cross-linker
Tissue transglutaminase (TG2) is upregulated in the pathogenesis of a wide variety of chronic diseases and similarities between the roles that TG2 plays in scar tissue and in the tumor stroma suggest that a deeper understanding of key common pathways in disease pathogenesis and progression might lead to the identification of novel treatment targets and the development of new drugs and diagnostic methods. Expand
Inhibition of the lncRNA Coded within Transglutaminase 2 Gene Impacts Several Relevant Networks in MCF-7 Breast Cancer Cells
The experiments strongly suggest the ability of TG2-lncRNA to directly interact with important transcription factors, such as RXRα and TP53, paving the way for several regulatory loops that can potentially influence the phenotypic behaviour of MCF-7 cells. Expand
VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype
VGLL4 suppresses the malignant epidermal SCC cancer phenotype by inhibiting YAP1/TEAD‐dependent pro‐cancer signaling and VGLL4 expression reduces tumor formation, and this is associated with reduced CCND1, CYR61, CTGF, COL1A2, andCOL1A3 mRNA and protein levels, and reduced EMT marker expression. Expand
The role of transglutaminase 2 in mediating glial cell function and pathophysiology in the central nervous system.
The interactions between glial cell types, and how TG2 in one cell type may affect another, are examined, as well as implications for specific TG2 populations as therapeutic targets in CNS pathology. Expand
Transglutaminase‐2, RNA‐binding proteins and mitochondrial proteins selectively traffic to MDCK cell‐derived microvesicles following H‐Ras‐induced epithelial–mesenchymal transition
It is shown that 21D1‐sMVs promote cell migration, confer anchorage‐independent growth, and induce EMT in parental MDCK cells, and the finding suggest that microvesicle‐associated TGM2 may play an important contributory role in the EMT process and warrants further investigation. Expand
Development of an 18F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues.
Robust and facile detection of the radiotracer-TGase 2 complex by autoradiography of thin layer plates and polyacrylamide gels after chromatographic and electrophoretic separation owing to irreversible covalent bond formation was demonstrated for the isolated protein, cell lysates, and living cells. Expand
High‐risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels
The aim of this study was to determine the proteomic effects of 3 FBXW7 mutations in high‐risk endometrial cancers (ECs) and to suggest novel treatment options for these cancers. Expand
Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu(HMC)-Gly-OH and its use for inhibitor and amine substrate characterisation.
A reliable solution-phase synthesis of the water-soluble dipeptidic fluorogenic transglutaminase substrate Z-Glu(HMC)-Gly-OH is presented and the advantage of this acyl donor substrate for the kinetic characterisation of inhibitors and amine-type acyl acceptor substrates is demonstrated. Expand


Transglutaminase is a tumor cell and cancer stem cell survival factor
The literature supports the idea thatTG2, in the closed/GTP‐binding/signaling conformation, drives cancer cell and cancer stem cell survival, and that TG2,in the open/crosslinking conformed, is associated with cell death. Expand
Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target
Evidence that TG2 can reprogram inflammatory signaling networks that play fundamental roles in cancer progression is discussed, suggesting that inhibiting TG2 may offer a novel therapeutic approach for managing and treatment of metastatic cancer. Expand
Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival
It is suggested that TG2 has an important role in maintaining cancer stem cell survival, invasive, and metastatic behavior and is an important therapeutic target to reduce survival of cancer stem cells in epidermal squamous cell carcinoma. Expand
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer
Recent evidence thatTG2-regulated pathways contribute to the aggressive phenotype in breast cancer is discussed, suggesting that TG2 plays a crucial role in promoting anaggressive phenotype in mammary epithelial cells. Expand
Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma
ABSTRACT Tissue transglutaminase (TG2) is the ubiquitously expressed member of transglutaminase family and shown to play a critical role in the development and progression of drug resistanceExpand
Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation
It is suggested that TG2 may serve as a mesothelioma cancer stem cell therapy target and TG2 loss is associated with reduced expression of stemness, and epithelial mesenchymal transition markers, and enhanced apoptosis. Expand
Transglutaminase 2 Promotes Migration and Invasion of Lung Cancer Cells.
The results show that TG2 plays a positive role in cell migration and invasion, and this might help metastasis of lung cancer cells, and exogenous application of recombinant TG2 protein to CL1-0 cells substantially augments cell migrationand invasion, suggesting the significance of extracellular TG2 in promoting these events. Expand
Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition
Analysis of a series of TG2 mutants reveals that TG2 GTP binding activity, but not the transamidase activity, is required for expression of EMT markers, and increased ECS cell invasion and migration, and suggests that inhibiting TG2GTP binding/G-protein related activity may reduce skin cancer tumor survival. Expand
Transglutaminase 3 protein modulates human esophageal cancer cell growth by targeting the NF-κB signaling pathway.
TGM3 can be a candidate tumor suppressor that is able to induce EC cell proliferation and migration by downregulating the NF-κB signaling pathway, indicating that TGM3 may serve as a useful biomarker and therapeutic target for EC treatment. Expand
Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway
It is observed that TG2 contributes to tumorigenesis and progression of GC by activating the ERK1/2 signaling pathway and is a potential therapeutic target of metastatic gastric cancer. Expand